Applied Research Systems Ars Holding N.v.

Laboratoires Serono S.a.

Merck Serono S. A.

Alexander Scheer

Anna Quattropani

Matthias Schwarz

Catherine Jorand-Lebrun

Vincent Pomel

Dennis Church

Russell Thomas

Jerome Dorbais

Serge Halazy

Anthony David Baxter

Catherine Joran-Lebrun

The present invention relates to sulfanilide derivatives of formula (I), in which Rand Rare optionally substituted aryl and heteroaryl groups and the other variables are as defined in the claims, for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such sulfanilide derivatives. Said derivatives are useful in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to sulfanilide derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and/or vasopressin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin and/or vasopressin, including preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. The present invention is furthermore related to novel sulfanilide derivatives as well as to methods of their preparation.

Pharmaceutically active sulfanilide derivatives

The present invention is related to pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR6R7, NOR6, NNR6R7; A is selected from the group consisting of &#x2014;(C&#x2550;O)&#x2014;, &#x2014;(C&#x2550;O)&#x2014;O&#x2014;, &#x2014;C(&#x2550;NH)&#x2014;, &#x2014;(C&#x2550;O)&#x2014;NH&#x2014;, &#x2014;(C&#x2550;S)&#x2014;NH, &#x2014;SO22-, &#x2014;SO2NH&#x2014;, &#x2014;CH2-, B is either a group &#x2014;(C&#x2550;O)&#x2014;NR8R9 or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5&#x2013;6 membered aryl or heteroaryl ring.

Pharmaceutically active pyrrolidine derivatives

The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I) to modulate, notably to antagonize the oxytocin receptor. The present invention is furthermore related to novel pyrrolidine esters. X is selected from the group consisting of CRR, NOR, NNRR; R is selected from the group comprising or consisting of C&#x2013;Calkyl, C&#x2013;Calkenyl, C&#x2013;Calkynyl, saturated or unsaturated 3&#x2013;8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, aryl, heteroaryl, C&#x2013;C-alkyl aryl, C&#x2013;C-alkyl heteroaryl. Ris selected from the group comprising or consisting of C&#x2013;C-alkyl, C&#x2013;C-alkenyl, C&#x2013;C-alkynyl, aryl, heteroaryl, 3&#x2013;8-membered cycloalkyl, acyl, C&#x2013;C-alkyl aryl, C&#x2013;C-alkyl heteroaryl, said cycloalkyl or aryl or heteroaryl groups may be fused with 1&#x2013;2 further cycloalkyl or aryl or heteroaryl group 

Pyrrolidine ester derivatives with oxytocin modulating activity

Growing community of inventors

Versoix, Switzerland

Alexander Scheer